Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

NCT04926831 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to recruitment challenges.

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: capmatinib

Sponsor

Novartis Pharmaceuticals